Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum

Rhea-AI Summary

Nasus Pharma (NYSE: NSRX) will present at the virtual Life Sciences Investor Forum on March 11, 2026 at 12:30 p.m. ET.

CEO Dan Teleman will deliver the presentation and Nasus management will be available for one-on-one meetings during the March 11-12, 2026 conference hosted by VirtualInvestorConferences.com.

News Market Reaction – NSRX

-15.43%

2 alerts

-15.43% Session close to close

+12.4% Peak Tracked

$54.10M Market Cap

0.8x Rel. Volume

In the Mar 9 session, NSRX declined 15.43%, reflecting a significant negative market reaction. Argus tracked a peak move of +12.4% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -15.4% in the session following this news. A negative reaction despite neutral con...

Analysis

The stock dropped -15.4% in the session following this news. A negative reaction despite neutral conference news would fit a pattern where enthusiasm around NS002 and capital markets activity has not always been rewarded consistently, as seen after positive Phase 2 data. Recent increases in authorized share capital and private placement activity could heighten sensitivity to dilution or governance concerns. Past instances show that even fundamentally positive developments have sometimes been followed by selling pressure, underscoring event-driven volatility.

Key Figures

Conference dates: March 11–12, 2026 Presentation time: 12:30 p.m. ET

2 metrics

Conference dates March 11–12, 2026 Life Sciences Investor Forum schedule

Presentation time 12:30 p.m. ET NSRX company presentation slot on March 11, 2026

Historical Context

5 past events · Latest: Feb 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 20	Investor conferences	Positive	+18.0%	Announced participation in three investor conferences with CEO presentations and meetings.
Feb 17	Clinical data preview	Positive	+1.0%	Planned AAAAI 2026 posters on superior nasal deposition and stability for NS002.
Feb 13	Private placement close	Positive	+5.4%	Closed $15.0M private placement of shares and warrants to fund NS002 and pipeline.
Feb 10	Private placement pricing	Positive	+2.9%	Announced pricing of $15.0M private placement to support pivotal NS002 study.
Jan 20	Phase 2 interim data	Positive	-7.5%	Reported positive interim Phase 2 NS002 PK and safety data versus EpiPen.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news, including clinical updates and financings, has usually aligned with positive price reactions, with one notable divergence on positive Phase 2 data.

Recent Company History

Over the last few months, Nasus Pharma has highlighted progress for its NS002 intranasal epinephrine program and strengthened its balance sheet. Positive interim Phase 2 results were followed by a $15.0M private placement and an F‑1 for resale registration. Investor outreach has intensified, with multiple conference appearances and data presentations such as AAAAI 2026. Today’s investor forum participation fits this pattern of broader capital markets and visibility efforts following key clinical milestones.

Key Terms

intranasal

1 terms

intranasal medical

"development of innovative intranasal products to treat emergency medical conditions"

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced that Company management will participate and present at the upcoming virtual Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com during March 11-12, 2026.

Presentation details

• Date and time: March 11, 2026, 12:30 p.m. ET
• Location: Virtual (Register HERE: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5270561/nasus-pharma-ltd-nyse-nsrx)
• Format: Company presentation
• Speaker: Dan Teleman, Chief Executive Officer

Nasus management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting.

About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’ intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus’ proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn.

Company Contact
Nasus Pharma Ltd.
info@nasuspharma.com

Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com

FAQ

When will Nasus Pharma (NSRX) present at the Life Sciences Investor Forum?

Nasus Pharma will present on March 11, 2026 at 12:30 p.m. ET. According to Nasus Pharma, CEO Dan Teleman is the scheduled speaker and the event is virtual as part of the March 11-12, 2026 Life Sciences Investor Forum.

Who is the speaker representing Nasus Pharma (NSRX) at the March 2026 conference?

The scheduled speaker is Dan Teleman, Chief Executive Officer. According to Nasus Pharma, management will also host one-on-one meetings during March 11-12, 2026 for investors and partners arranged via the conference representative.

How can investors register to attend the Nasus Pharma (NSRX) presentation on March 11, 2026?

Investors can register via the conference platform's registration link provided by the host. According to Nasus Pharma, attendees should use VirtualInvestorConferences.com registration and contact their conference representative to arrange one-on-one meetings.

Will Nasus Pharma (NSRX) offer one-on-one meetings during the Life Sciences Investor Forum?

Yes, Nasus management will be available for one-on-one meetings during March 11-12, 2026. According to Nasus Pharma, interested parties must contact their conference representative to schedule meetings with company management.

Where is the Life Sciences Investor Forum presentation by Nasus Pharma (NSRX) being hosted?

The presentation is hosted virtually by VirtualInvestorConferences.com on March 11-12, 2026. According to Nasus Pharma, the March 11 session at 12:30 p.m. ET will be delivered by CEO Dan Teleman and is accessible online via registration.